Gilead touts pivotal data for new kind of HIV therapy, opening towards large potential market
Pandemic aside, the last couple years at Gilead have been all about expansions: Moving beyond the HIV and hepatitis C antivirals that made them into a $77 billion company and into the immunology and oncology treatments that have become biotech’s bread and butter.
Still, key HIV projects have continued as the California biotech looks to stay on top of a field that still earns them north of $15 billion per year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.